source
- Tarsus to acquire Alkeus for $450 million, adding phase-3 retinal drug and oral Stargardt candidateTarsus Pharmaceuticals announced it will buy Alkeus Pharmaceuticals in a transaction valued at $450 million. The deal consists of $270 million in cash and $180 million of Tarsus common stock, givi…
- BioVie’s Parkinson drug data prompts 50% stock drop as company shifts to composite endpointBioVie announced phase 2 results for its experimental Parkinson’s therapy bezisterim, saying the data suggest a meaningful advance in treating the disease. Investors reacted sharply, wiping out ro…